文献速递浆细胞疾病

AL淀粉样变性抗浆细胞治疗后肾脏反应的预测因素:基线血清游离轻链水平与轻链同型的影响

Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype.
PubMed 文献 · Br J Haematol · 2026-05-10

该回顾性研究纳入2010至2022年间350例可评估肾脏反应的新诊断AL淀粉样变性患者,分析抗浆细胞治疗后肾脏反应的相关因素。多因素分析显示6个月内达到≥血液学VGPR、kappa同型、基线dFLC≥40 mg/dL、肾脏分期及自体造血干细胞移植与深度肾脏反应显著相关。

要点

  • 6个月内达到≥血液学VGPR与深度肾脏反应显著相关
  • kappa轻链同型及基线dFLC≥40 mg/dL独立影响肾脏反应时机与深度
  • 一线自体造血干细胞移植及较低肾脏分期提高深度肾脏反应可能性

核心结论

  • 特定克隆性浆细胞特征(轻链同型及基线dFLC水平)独立影响AL淀粉样变性治疗后肾脏反应的时机与深度。

研究设计与样本

  • 回顾性研究,纳入2010至2022年间新诊断AL淀粉样变性患者350例,均可评估肾脏反应,中位年龄64岁,中位随访5.5年。

主要发现

  • 多因素logistic回归显示6个月内达到≥血液学VGPR、kappa同型、基线dFLC≥40 mg/dL、肾脏分期及自体造血干细胞移植与深度肾脏反应显著相关。
  • 以死亡或肾脏进展为竞争事件,累积发生率显示早期血液学反应、一线自体造血干细胞移植、较低肾脏分期及dFLC≥40 mg/dL显著增加深度肾脏反应的可能性。
  • 肾脏反应在第6、12、24个月及最佳反应时记录,深度肾脏反应定义为≥肾脏VGPR(24小时蛋白尿下降>60%或≤200 mg)。

关键数值与推荐

  • 深度肾脏反应定义为≥肾脏VGPR:24小时蛋白尿下降>60%或≤200 mg。
  • 基线dFLC≥40 mg/dL与深度肾脏反应显著相关。
  • 6个月内达到≥血液学VGPR与深度肾脏反应显著相关。

临床怎么用

  • 对于新诊断AL淀粉样变性患者,应关注基线dFLC水平及轻链同型以预判肾脏反应。
  • 争取6个月内达到≥血液学VGPR,并考虑一线自体造血干细胞移植以提高深度肾脏反应可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal response (RenR) in light-chain (AL) amyloidosis is associated with a lower risk of end-stage kidney disease and improved survival. However, substantial variation exists in the time to and depth of RenR. We investigated variables associated with RenR in a retrospective study of newly diagnosed AL amyloidosis patients (n = 350) assessable for RenR between 2010 and 2022. RenRs were recorded at 6, 12 and 24 months and best response. Deep RenR was defined as a ≥renal very good partial response (RenVGPR, >60% reduction in 24-h proteinuria or ≤200 mg). Logistic regression and competing risk methods were used to examine variables associated with RenR. The median age was 64 years, and median follow-up was 5.5 years. On multivariable logistic regression, obtaining ≥HemVGPR within 6 months, kappa isotype, high baseline difference between involved and uninvolved free light chains (dFLC ≥40 mg/dL), renal stage and autologous haematopoietic stem cell transplant (AHSCT) were significantly associated with deep RenR. Cumulative incidence rates for deep RenR, treating death or renal progression as a competing event, demonstrated that early HemR, first-line AHSCT, lower renal stage and dFLC ≥40 mg/dL significantly increased the likelihood of deep RenR. Specific clonal plasma cell features, namely light-chain isotype and baseline dFLC levels, independently influence the timing and depth of RenRs in AL amyloidosis following treatment, in addition to renal stage and HemR.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rees MJ, Yohannan B, Geyer S, et al. Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype. Br J Haematol. 2026. PMID: 42108212. doi:10.1111/bjh.70542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。